SEC Tracker
Get the app
VKTX · XBRL financial data

Viking Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (VKTX's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue from contracts with customers0*0000*0000*000
Research and development21*24242331*416090153*150116167
General and administrative9*10101415*1414911*141720
Total operating expenses29*34343746*557599165*164133187
Operating income (loss)(29)*(34)(34)(37)(46)*(55)(75)(99)(165)*(164)(133)(187)
Interest income———————8———4
Interest expense———————0———0
Other income (expense)5*7121211*10987*654
Income tax expense (benefit)year only———year only———year only———
Net income (loss)(25)*(27)(22)(25)(35)*(46)(66)(91)(158)*(158)(128)(183)
Earnings per share, basic USD per share(0.25)*(0.26)(0.20)(0.22)(0.32)*(0.41)(0.58)(0.81)(1.38)*(1.37)(1.10)(1.55)
Earnings per share, diluted USD per share(0.25)*(0.26)(0.20)(0.22)(0.32)*(0.41)(0.58)(0.81)(1.38)*(1.37)(1.10)(1.55)
Weighted average shares, basic millions of shares100*103110111111*112112112114*116116118
Weighted average shares, diluted millions of shares100*103110111111*112112112114*116116118

Balance sheet

CSV

Fiscal quarters (VKTX's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents561964450273834100166118126678
Marketable securities307767898880876814774614540485376282
Prepaid and other current assets310211322113
Total current assets367966946937907866827739716608518973
Right-of-use asset111111110044
Total assets368968947938908867828739716608522977
Accounts payable851101085453676982
Total current liabilities193325262720322677106110134
Lease liability, non-current111111000044
Total liabilities203426262820322677106114389
Accumulated deficit(378)(405)(428)(452)(488)(534)(599)(690)(848)(1,006)(1,134)(1,317)
Total stockholders' equity348934921911880847795713639502408589
Total liabilities and equity368968947938908867828739716608522977
Common shares outstanding (cover page) millions of shares100110111111112112112113116116117128

Cash flows

CSV

Fiscal quarters (VKTX's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(25)*(27)(22)(25)(35)*(46)(66)(91)(158)*(158)(128)(183)
Stock-based compensation4*8796*111479*101118
Net cash from operating activities(18)*(6)(29)*(22)*(31)*(52)(47)*(94)*(85)*(114)(125)*(138)*
Net cash from investing activities36*(460)(126)*26*7*6343*160*76*54109*93*
Net cash from financing activities0*6063*3*1*01*0*75*1224*598*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Viking Therapeutics6780(138)*127.5M7.6 quarters 10-QSep 30, 2026
Prestige Consumer Healthcare892667147.4M— 10-QJun 30, 2026
Protagonist Therapeutics420213219*64.7M— 10-QJun 30, 2026
Ultragenyx Pharmaceutical125214(97)*98.6M3.0 quarters 10-QJun 30, 2026
Avidity Biosciences3830.9*(170)*155.1M2.3 quarters 10-KDec 31, 2025
Catalyst Pharmaceuticals75614960122.4M— 10-QMar 31, 2026
Cytokinetics25529(160)*139.0M7.3 quarters 10-QJun 30, 2026
TG Therapeutics48324039*153.1M— 10-QJun 30, 2026
Summit Therapeutics419not reported(141)*797.7M4.9 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.